Androgen News and Research

RSS

Therapeutic breaks for prostate cancer patients

Men with advanced prostate cancer receiving androgen-deprivation therapy may be better off being treated intermittently rather than on a continuous basis, show study findings.

15 Aug 2012

Spectrum Pharmaceuticals initiates enrollment in Phase 2b ozarelix study for prostate cancer

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced initiation of patient enrollment in the second part of the Company's randomized Phase 2 clinical program of ozarelix, a luteinizing hormone-releasing hormone (LHRH) antagonist, in men with prostate cancer for whom hormonal treatment is indicated.

15 Aug 2012

High BMI linked to poor outcomes after prostatectomy and ADT

Men initiating androgen deprivation therapy after radical prostatectomy are more likely to experience poor outcomes if they are overweight or obese, report researchers.

8 Aug 2012

GTx reports revenue of $1.6 million for second quarter 2012

GTx, Inc. today provided a Company update and reported financial results for the second quarter of 2012.

8 Aug 2012

Calcium and vitamin D supplements do not prevent bone loss in men with prostate cancer

Prescribing calcium and vitamin D supplements for men at risk of bone loss from hormonal treatment for prostate cancer seems like good medicine.

8 Aug 2012

Older men with higher levels of free testosterone more likely to develop prostate cancer

New research finds older men with higher levels of free testosterone have an increased risk of prostate cancer. Australian researchers spent a decade exploring the testosterone-prostate cancer connection by comparing natural testosterone levels of men in their 70s and 80s, those with prostate cancer and without.

8 Aug 2012

Debiopharm initiates Debio 8206 Phase III study on advanced prostate cancer

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, today announced the treatment of its first patient in a multicentre, open, non-comparative Phase III study to investigate the efficacy, safety, and pharmacokinetics of two subcutaneous (SC) injections of Debio 8206 (triptorelin pamoate 22.5 mg 6-month formulation) in patients with advanced prostate cancer.

24 Jul 2012

Estrogen may mediate low incidence of HCC in women

Study findings suggest that estrogen may have a suppressive effect on hepatocellular carcinoma, potentially explaining its lower incidence in women.

18 Jul 2012

Targeted regulation of microRNA-125b may lead to effective prostate cancer therapies

A small, naturally occurring nucleic acid sequence, called a microRNA, known to regulate a number of different cancers, appears to alter the activity of the androgen receptor, which plays a critical role in prostate cancer.

18 Jul 2012

Combination of Dox with MCP shows promise against prostate cancer

Doxorubicin (Dox) is an effective anti-cancer drug, but it's also a very toxic one, causing severe heart and immune damage. The doses needed to impact tumors are not well tolerated by patients, however, researchers may have found an answer through combination therapy.

18 Jul 2012

Prostate cancer treatment regrets linked to comorbidity

Men with cardiovascular disease are significantly more likely to regret their prostate cancer treatment choice than men without this comorbidity and have an increased risk for adverse effects, US researchers warn.

16 Jul 2012

Prostate cancer patients with CVD are 52% more likely to regret their treatment choices

Prostate cancer patients with cardiovascular disease were 52 per cent more likely to regret their treatment choices than men without problems with their heart or veins, according to a study published in the July issue of the urology journal BJUI International.

3 Jul 2012

Astellas submits enzalutamide MAA with EMA for treatment of CRPC

Today, Astellas Pharma Inc. announces the submission of a European marketing authorisation application to the European Medicines Agency (EMA) for enzalutamide for the treatment of men with metastatic castration-resistant prostate cancer who have been previously treated with docetaxel-based chemotherapy.

27 Jun 2012

Experimental medication increases muscle strength in cancer patients with low testosterone levels

An experimental medication safely increases muscle strength and physical functioning among cancer patients with low testosterone levels, a new drug study finds. The results will be presented Sunday at The Endocrine Society's 94th Annual Meeting in Houston.

26 Jun 2012

Review describes new classes of drugs that target androgens in novel ways

Prostate cancer cells require androgens including testosterone to grow. A recent review in the British Journal of Urology International describes new classes of drugs that target androgens in novel ways, providing alternatives to the traditional methods that frequently carry high side effects.

21 Jun 2012

Six novel genetic associations for early onset male pattern baldness

Using data from its unique online research platform, 23andMe, a leading personal genetics company, has contributed to the finding of six novel genetic associations for early onset male pattern baldness (androgenetic alopecia) in a genome-wide association study now published online in the journal PLoS Genetics.

20 Jun 2012

Compounds related to curcumin receive U.S. patent

A U.S patent issued today to the University of Rochester and two other entities for the use of compounds related to a popular spice in the fight against cancer, acne, baldness, and other medical conditions.

13 Jun 2012

CCR5 antagonists may also help prevent aggressive breast cancers from metastasizing

The HIV drugs known as CCR5 antagonists may also help prevent aggressive breast cancers from metastasizing, researchers from the Kimmel Cancer Center at Jefferson suggest in a preclinical study published in a recent issue of Cancer Research.

7 Jun 2012

Split-course RT valuable after hormone-resistant prostate cancer relapse

A split course of high-dose radiotherapy in men with progressive, hormone-refractory prostate cancer is effective and has an acceptable toxicity profile, report Australian researchers.

6 Jun 2012

Ipsen, Active Biotech present OS data from tasquinimod Phase II study on CRPC at ASCO 2012

Active Biotech and Ipsen today presented overall survival (OS) data from the tasquinimod Phase II study in chemotherapy-naïve metastatic castrate resistant prostate cancer (CRPC) at the scientific conference "2012 ASCO Annual Meeting" held in Chicago (USA).

5 Jun 2012

Androgen News and Research

Therapeutic breaks for prostate cancer patients

Spectrum Pharmaceuticals initiates enrollment in Phase 2b ozarelix study for prostate cancer

High BMI linked to poor outcomes after prostatectomy and ADT

GTx reports revenue of $1.6 million for second quarter 2012

Calcium and vitamin D supplements do not prevent bone loss in men with prostate cancer

Older men with higher levels of free testosterone more likely to develop prostate cancer

Debiopharm initiates Debio 8206 Phase III study on advanced prostate cancer

Estrogen may mediate low incidence of HCC in women

Targeted regulation of microRNA-125b may lead to effective prostate cancer therapies

Combination of Dox with MCP shows promise against prostate cancer

Prostate cancer treatment regrets linked to comorbidity

Prostate cancer patients with CVD are 52% more likely to regret their treatment choices

Astellas submits enzalutamide MAA with EMA for treatment of CRPC

Experimental medication increases muscle strength in cancer patients with low testosterone levels

Review describes new classes of drugs that target androgens in novel ways

Six novel genetic associations for early onset male pattern baldness

Compounds related to curcumin receive U.S. patent

CCR5 antagonists may also help prevent aggressive breast cancers from metastasizing

Split-course RT valuable after hormone-resistant prostate cancer relapse

Ipsen, Active Biotech present OS data from tasquinimod Phase II study on CRPC at ASCO 2012

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News